| Literature DB >> 35782448 |
Yanwei Cheng1, Yiwen Wang1, Xiangyi Wang1, Zhuoya Jiang1, Lijun Zhu2, Shaokuan Fang1.
Abstract
Background: Research on neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) in depression is still emerging and has increased 3-fold since the first meta-analysis. An updated meta-analysis with sufficient studies can provide more evidence for a potential relationship between NLR, PLR, MLR, and depression.Entities:
Keywords: depression; meta-analysis; monocyte-to-lymphocyte ratio; neutrophil-to-lymphocyte ratio; platelet-to-lymphocyte ratio
Year: 2022 PMID: 35782448 PMCID: PMC9240476 DOI: 10.3389/fpsyt.2022.893097
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 5.435
Figure 1Flowchart of literature search and selection.
Main characteristics of studies included in the meta-analysis.
|
|
|
|
|
|
|
|
| ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||||||
| Hu et al. ( | China | PSD | DSM-IV, HAMD-17 >7 | Yes | 129 | 62.0 ± 10.9 | 75 | 294 | 62.8 ± 10.0 | 197 | NLR, PLR |
| Ding et al. ( | China | PSD | DSM-IV, HAMD-17 >7 | Yes | 44 | 68.11 ± 8.73 | 30 | 159 | 66.16 ± 11.15 | 108 | MLR |
| Bulut et al. ( | Turkey | MDD | DSM-V | Yes | 93 | 41.37 ± 13.69 | 40 | 95 | 39.81 ± 12.96 | 40 | NLR, PLR |
| Zhou et al. ( | China | MDD | DSM-IV | Yes | 454 | 53.08 ± 9.20 | 129 | 458 | 53.02 ± 6.75 | 147 | NLR, PLR, MLR |
| Yu et al. ( | China | MDD | DSM-V | Yes | 82 | 21.06 ± 11.14 | 36 | 120 | 22.63 ± 8.87 | 54 | NLR, PLR, MLR |
| Sahin et al. ( | Turkey | MDD | DSM-V, HAMD >7 | Yes | 57 | 39.79 ± 13.26 | 27 | 59 | 41.54 ± 15.48 | 22 | NLR, PLR |
| Martínez-Botía et al. ( | Spain | MDD | DSM-V | No | 71 | 52.90 ± 10.46 | 32 | 93 | 48.22 ± 11.44 | 53 | NLR, PLR, MLR |
| Hu et al. ( | China | PSD | DSM-IV | No | 104 | 61.74 ± 10.52 | 53 | 272 | 60.64 ± 10.02 | 171 | NLR PLR |
| Grudet et al. ( | USA | MDD | DSM-IV, HAMD-17 ≥17 | Yes | 48 | 39.3 ± 14.9 | 21 | 54 | 37.9 ± 13.9 | 21 | NLR |
| Öztürk et al. ( | Turkey | MDD | DSM-IV | Yes | 49 | 40.86 ± 14.7 | 13 | 48 | 36.85 ± 10.1 | 12 | NLR |
| Arabska et al. ( | Poland | MDD | ICD-10 | No | 465 | 74.8 ± 7.9 | 110 | 219 | 71.1 ± 5.6 | 48 | NLR |
| Euteneuer et al. ( | Germany | MDD | DSM-IV | Yes | 98 | 37.3 ± 12.2 | 50 | 30 | 37.1 ± 12.2 | 15 | NLR |
| Ekinci and Ekinci ( | Turkey | MDD | DSM-IV | Yes | 139 | 42.18 ± 12.21 | 42 | 50 | 44.12 ± 4.23 | 13 | NLR, PLR |
| Cai et al. ( | China | MDD | DSM-IV, HAMD ≥10 | Yes | 103 | 46.58 ± 13.38 | 46 | 106 | 46.56 ± 12.94 | 47 | NLR, PLR |
| Peng et al. ( | China | MDD | DSM-IV | Yes | 167 | 38.2 ± 9.56 | 54 | 180 | 39.1 ± 10.64 | 67 | NLR, PLR |
| Korkmaz et al. ( | Turkey | MDD | DSM-IV | Yes | 40 | 43 ± 12 | 17 | 40 | 43 ± 8 | 18 | NLR |
| Demircan et al. ( | Turkey | MDD | DSM-IV | Yes | 80 | 44.10 ± 10.60 | 44 | 91 | 39.80 ± 11.50 | 49 | NLR |
| Demir et al. ( | Turkey | MDD | DSM-V | Yes | 41 | 28.4 ± 9.2 | 11 | 47 | 30.0 ± 9.2 | 12 | NLR |
PSD, post-stroke depression; MDD, major depressive disorder; DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, International Classification of Diseases; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio.
Comparison of NLR, PLR, MLR between patients with depression and controls.
|
|
|
|
| ||
|---|---|---|---|---|---|
| NLR | Hu et al. ( | 3.01 ± 2.01 | 129 | 2.21 ± 0.88 | 294 |
| Bulut et al. ( | 2.25 ± 1.50 | 93 | 1.67 ± 0.78 | 95 | |
| Zhou et al. ( | 2.09 ± 1.45 | 454 | 2.00 ± 0.73 | 458 | |
| Yu et al. ( | 1.99 ± 1.18 | 82 | 1.78 ± 0.55 | 120 | |
| Sahin et al. ( | 2.60 ± 1.10 | 57 | 1.90 ± 0.62 | 59 | |
| Martínez-Botía et al. ( | 2.01 ± 1.42 | 71 | 1.87 ± 0.80 | 93 | |
| Hu et al. ( | 3.67 ± 1.59 | 104 | 3.13 ± 1.23 | 272 | |
| Grudet et al. ( | 2.2 ± 0.9 | 48 | 2.3 ± 1.2 | 54 | |
| Öztürk et al. ( | 2.29 ± 1.02 | 49 | 2.09 ± 0.95 | 48 | |
| Arabska et al. ( | 1.78 ± 1.31 | 465 | 1.95 ± 0.73 | 219 | |
| Euteneuer et al. ( | 2.0 ± 0.7 | 98 | 1.6 ± 0.6 | 30 | |
| Ekinci and Ekinci ( | 2.12 ± 0.95 | 139 | 1.81 ± 0.33 | 50 | |
| Cai et al. ( | 2.28 ± 0.62 | 103 | 2.0 ± 0.73 | 106 | |
| Peng et al. ( | 1.9 ± 0.73 | 167 | 1.7 ± 0.62 | 180 | |
| Korkmaz et al. ( | 1.58 ± 0.59 | 40 | 2.05 ± 0.89 | 40 | |
| Demircan et al. ( | 2.55 ± 0.70 | 80 | 1.41 ± 0.8 | 91 | |
| Demir et al. ( | 2.3 ± 0.9 | 41 | 2.0 ± 0.6 | 47 | |
| PLR | Hu et al. ( | 125.02 ± 44.40 | 129 | 118.92 ± 40.22 | 294 |
| Bulut et al. ( | 128.78 ± 59.63 | 93 | 110.67 ± 41.86 | 95 | |
| Zhou et al. ( | 127.86 ± 52.45 | 454 | 117.20 ± 36.97 | 458 | |
| Yu et al. ( | 134.28 ± 47.09 | 82 | 113.12 ± 22.57 | 120 | |
| ( | 122.67 ± 43.92 | 57 | 141.11 ± 48.32 | 59 | |
| ( | 119.49 ± 55.27 | 71 | 117.99 ± 54.77 | 93 | |
| Hu et al. ( | 195.25 ± 112.26 | 104 | 120.19 ± 44.15 | 272 | |
| Ekinci and Ekinci ( | 131.65 ± 59.86 | 139 | 134.3 ± 61.4 | 50 | |
| Cai et al. ( | 128.69 ± 29.73 | 103 | 118.79 ± 32.84 | 106 | |
| Peng et al. ( | 125.3 ± 37.99 | 167 | 124.4 ± 59.15 | 180 | |
| MLR | Ding et al. ( | 0.28 ± 0.08 | 44 | 0.24 ± 0.09 | 159 |
| Zhou et al. ( | 0.18 ± 0.08 | 454 | 0.16 ± 0.05 | 458 | |
| Martínez-Botía et al. ( | 0.26 ± 0.11 | 71 | 0.30 ± 0.13 | 93 | |
NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio.
Mean and standard deviation are estimated from median and interquartile range according to McGrath et al.'s method.
Figure 2Results of meta-analysis on NLR between depressed patients and controls. (A) Forest plot of standardized mean difference in NLR between depressed patients and controls. Depressed patients showed significantly higher NLR values than controls (SMD = 0.33, 95% CI: 0.15–0.52, p < 0.001). The random-effects model was used due to substantial heterogeneity across studies (I2 = 87.6%, p < 0.001). (B) Sensitivity analysis revealed that the SMD values were relatively stable in the direction and significance of the results. (C) The funnel plot was roughly symmetric, which indicated the absence of publication bias in studies evaluating NLR values in depression.
Summary of meta-analyses.
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
|
| 17 | Random | 0.33 | 0.15–0.52 | 87.6% | 0.000 | 3.55 | 0.000 |
|
| ||||||||
| China | 6 | Random | 0.33 | 0.16–0.51 | 75.4% | 0.001 | 3.72 | 0.000 |
| Turkey | 7 | Random | 0.46 | 0.01–0.90 | 90.4% | 0.000 | 2.01 | 0.044 |
| Other country | 4 | Random | 0.09 | −0.21 to 0.39 | 74.3% | 0.009 | 0.58 | 0.564 |
|
| ||||||||
| MDD | 15 | Random | 0.308 | 0.104–0.512 | 87.8% | 0.000 | 2.95 | 0.003 |
| PSD | 2 | Fixed | 0.51 | 0.36–0.67 | 36.3% | 0.210 | 6.46 | 0.000 |
|
| ||||||||
| DSM | 16 | Random | 0.37 | 0.19–0.55 | 85.1% | 0.000 | 3.96 | 0.000 |
| ICD-10 | 1 | / | −0.15 | −0.31 to 0.01 | / | / | 1.79 | 0.073 |
|
| ||||||||
| Yes | 14 | Random | 0.38 | 0.17–0.59 | 86.8% | 0.000 | 3.58 | 0.000 |
| No | 3 | Random | 0.12 | −0.24 to 0.48 | 86.9% | 0.000 | 0.66 | 0.512 |
|
| ||||||||
| Yes | 3 | Random | 1.34 | −0.61 to 3.30 | 97.6% | 0.000 | 1.35 | 0.178 |
| No | 3 | Fixed | −0.07 | −0.29 to 0.16 | 0.0% | 0.557 | 0.58 | 0.563 |
|
| 10 | Random | 0.24 | 0.02–0.46 | 88.0% | 0.000 | 2.15 | 0.031 |
|
| ||||||||
| China | 6 | Random | 0.39 | 0.11–0.68 | 90.8% | 0.000 | 2.70 | 0.007 |
| Turkey | 3 | Random | −0.02 | −0.44 to 0.41 | 80.5% | 0.006 | 0.08 | 0.933 |
| Spain | 1 | / | 0.03 | −0.28 to 0.34 | / | / | 0.17 | 0.863 |
|
| ||||||||
| MDD | 8 | Random | 0.16 | −0.02 to 0.33 | 73.3% | 0.000 | 1.75 | 0.080 |
| PSD | 2 | Random | 0.61 | −0.30 to 1.52 | 97.0% | 0.000 | 1.31 | 0.189 |
|
| ||||||||
| Yes | 8 | Random | 0.17 | 0.01–0.33 | 72.4% | 0.001 | 2.05 | 0.041 |
| No | 2 | Random | 0.56 | −0.47 to 1.58 | 96.4% | 0.000 | 1.06 | 0.289 |
|
| ||||||||
| Yes | 2 | Fixed | 0.12 | −0.15 to 0.40 | 0.0% | 0.882 | 0.88 | 0.378 |
| No | 2 | Fixed | −0.14 | −0.41 to 0.12 | 0.0% | 0.821 | 1.04 | 0.297 |
|
| 3 | Random | 0.15 | −0.26 to 0.55 | 86.8% | 0.000 | 0.71 | 0.475 |
|
| ||||||||
| China | 2 | Fixed | 0.32 | 0.20–0.44 | 0.0% | 0.401 | 5.16 | 0.000 |
| Spain | 1 | / | −0.33 | −0.64 to −0.02 | / | / | 2.07 | 0.038 |
|
| ||||||||
| MDD | 2 | Random | 0.00 | −0.61 to 0.62 | 92.5% | 0.000 | 0.01 | 0.994 |
| PSD | 1 | / | 0.46 | 0.12–0.79 | / | / | 2.65 | 0.008 |
|
| ||||||||
| Yes | 2 | Fixed | 0.32 | 0.20–0.44 | 0.0% | 0.401 | 5.16 | 0.000 |
| No | 1 | / | −0.33 | −0.64 to −0.02 | / | / | 2.07 | 0.038 |
NLR neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; MDD, major depressive disorder; PSD, post-stroke depression; DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, International Classification of Diseases; SMD, standardized mean differences; 95% CI, 95% confidence interval; P.
Results of meta-regression analysis.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
| |||||
| Age in case group | −0.005 | 0.009 | −0.022 to 0.013 | −0.56 | 0.583 |
| Male proportion in case group | 1.986 | 0.904 | 0.059–3.912 | 2.20 | 0.044 |
| Age in control group | −0.006 | 0.009 | −0.025 to 0.014 | −0.62 | 0.547 |
| Male proportion in control group | 1.086 | 0.783 | −0.583 to 2.755 | 1.39 | 0.186 |
|
| |||||
| Age in case group | 0.005 | 0.011 | −0.021 to 0.031 | 0.48 | 0.646 |
| Male proportion in case group | 1.092 | 1.389 | −2.111 to 4.295 | 0.79 | 0.454 |
| Age in control group | 0.005 | 0.012 | −0.023 to 0.032 | 0.41 | 0.696 |
| Male proportion in control group | 1.338 | 0.922 | −0.788 to 2.464 | 1.45 | 0.185 |
NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; 95% CI, 95% confidence interval.
Figure 3Results of meta-analysis on PLR between depressed patients and controls. (A) Forest plot of standardized mean difference in PLR between depressed patients and controls. The PLR values were distinctly higher in depressed patients than in controls (SMD = 0.24, 95% CI: 0.02–0.46, p < 0.05). Due to significant heterogeneity among studies (I2 = 88.0%, p < 0.001), the random-effects model was applied. (B) Sensitivity analysis indicated an unstable result of this meta-analysis. (C) The funnel plot appeared to be symmetric, which suggested no publication bias in studies reporting the values of PLR in depressed patients and controls.
Figure 4Results of meta-analysis on MLR between depressed patients and controls. (A) Forest plot Forest plot of standardized mean difference in MLR between depressed patients and controls. Depressed patients had slightly higher MLR than controls without a significant difference (SMD = 0.15, 95% CI: −0.26 to 0.55; p > 0.05). Heterogeneity among three studies remained high (I2 = 86.8%, p < 0.001) and the random-effects model was used. (B) Sensitivity analysis suggested that the results of the meta-analysis were unstable.
Figure 5Interactions among peripheral blood cells and their involvement in the mechanisms of neuroinflammation induced depressive symptoms. In the presence of an inflammatory stimulus or infection, in addition to playing a role in recognizing, phagocytosis and killing pathogens, neutrophils can also interact with adaptive immunity. On the one hand, neutrophils can migrate to the spleen and induce T1 antibodies production by activating B cells through the productions of BAFF, APRIL and IL-21; while production of T1 antibodies helps to increase the phagocytic and clearance capabilities of neutrophils. On the other hand, neutrophils can facilitate the activation and differentiation of T cells through several following pathways: present antigens directly; by the release of NETs; acting as APCs; transfer antigens to dendritic cells. Monocytes can migrate into systemic tissue and differentiate into macrophages and dendritic cells, and play three major functions in immune responses: phagocytosis, antigen presentation, and cytokine production. For lymphocytes, they are the main effectors of adaptive immunity which facilitate pathogen-specific immune recognition, antibody, cytokine and immune memory production, cytotoxicity, and so on. Platelets are important effectors of innate and adaptive immunity: interact with neutrophils mediated by the P-selectin/PSGL1 axis; form the platelet-monocyte complexes through binding of platelet-expressed CXCR1 to CXCL1 of monocytes; facilitate T cell trafficking or regulate T cell functions. In addition, platelets can release serotonin, dopamine, glutamate, and so on. Chronic stress can disrupt the blood-brain barrier and increase access of peripheral cells to infiltrate directly into the brain. After migration into brain lesions, peripheral inflammatory cells (neutrophils, monocytes, and lymphocytes) may exacerbate brain injury and neuronal damage by releasing pro-inflammatory cytokines and NETs, and producing reactive oxygen species and reactive nitrogen species. neuroinflammation is orchestrated by resident immune cells such as microglia and astrocytes, as well as neutrophils, monocytes, and lymphocytes migrating from the periphery. It is able to influence depressive symptoms by impairing monoamine neurotransmitter synthesis, affecting glutamatergic signaling, and altering neurogenesis and synaptic plasticity. APC, antigen-presenting cell; APRIL, a proliferation-inducing ligand; BAFF, B cell activating factor; CXCL1, (C-X3-C Motif) Receptor 1; CXCRL, (C-X3-C Motif) Receptor 1; DC, dendritic cell; IDO, indoleamine 2,3-dioxygenase; IL, interleukin; KAT, kynurenine aminotransferase; KMO, kynurenine 3-monooxygenase; NETs, neutrophil extracellular traps; NMDAR, N-methyl-D-aspartate receptor; P-selectin, platelet selectin; PSGL1, P-selectin glycoprotein ligand 1; TNF, tumor necrosis factor.